CoChat

Albumin-recruiting lipid nanoparticle potentiates the safety and efficacy of mRNA vaccines by avoiding liver accumulation

Feng, Yunxuan, Tai, Wanbo, Huang, Pei, Qi, Shaolong, Yu, Xinyang, Li, Mengfei, Li, Mengyao, Zhang, Miya, Cao, Fangfang, Gao, Xiaomin, Yang, Kai, Bai, Bing, Lei, Jiaqi, Cheng, Meiqi, Li, Yongcan, Cheng, Gong, Chen, Xiaoyuan, Yu, Guocan · 2025 · Nature Materials
Cited by 66

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

The advent of mRNA vaccines represents a breakthrough in the realm of cancer therapy and the prevention of infectious disease. Nevertheless, traditional lipid nanoparticle (LNP)-based mRNA vaccines can accumulate in the liver post-intramuscular injection, posing a risk of hepatotoxicity and reducing efficacy. Here we develop an albumin-recruiting LNP system with high lymphatic drainage and no accumulation in hepatic tissue to potentiate the efficacy and safety of mRNA vaccines. We construct a library of ionizable lipids with albumin-binding capacity as alternatives to traditional polyethylene-glycol-conjugated lipid. We identify an Evans blue-modified lipid-based LNP (EB-LNP) formulation that shows high in vivo expression, albumin-facilitated transport through intramuscular lymphatic vessels to the lymph nodes, high internalization by dendritic cells and low penetration into intramuscular blood vessels, thereby avoiding liver accumulation. EB-LNP-based mRNA vaccines demonstrate excellent antitumour and antiviral efficacy, resulting in strong cellular and humoral immune responses, including the robust activation of cytotoxic T lymphocytes and production of neutralizing antibodies post-vaccination. Overall, this system shows promise as an effective and minimally toxic platform for the development of mRNA vaccines with high efficacy and safety.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41563-025-02284-w

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 12 references

Research works printed but not linked: 41

  1. Pardi, N. & Krammer, F. mRNA vaccines for infectious diseases—advances, challenges and opportunities. Nat. Rev. Drug. Discov. 23, 838–861 (2024). · DOI · Paper page
  2. Ju, Y. et al. Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines. Nat. Rev. Immunol. 23, 135–136 (2023). · DOI · Paper page
  3. Chen, J. et al. Current developments and challenges of mRNA vaccines. Annu. Rev. Biomed. Eng. 24, 85–109 (2022). · DOI
  4. Pateev, I. et al. Biodistribution of RNA vaccines and of their products: evidence from human and animal studies. Biomedicines 12, 59 (2023). · DOI
  5. Ye, Z. et al. Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants. Proc. Natl Acad. Sci. USA 120, e2311752120 (2023).
  6. Shi, Y. et al. Structural and biochemical characteristics of mRNA nanoparticles determine anti-SARS-CoV-2 humoral and cellular immune responses. Sci. Adv. 8, eabo1827 (2022). · DOI
  7. Chen, J. et al. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response. Proc. Natl Acad. Sci. USA 119, e2207841119 (2022).
  8. Kitagawa, H. et al. Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan. J. Infect. Chemother. 28, 576–581 (2022). · DOI
  9. Schinas, G. et al. Immune-mediated liver injury following COVID-19 vaccination. World J. Virol. 12, 100–108 (2023). · DOI
  10. Efe, C. et al. Liver injury after SARS-CoV-2 vaccination: features of immune-mediated hepatitis, role of corticosteroid therapy and outcome. Hepatology 76, 1576–1586 (2022). · DOI · Paper page
  11. Boettler, T. et al. SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis. J. Hepatol. 77, 653–659 (2022). · DOI
  12. Zin Tun, G. S. et al. Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed. J. Hepatol. 76, 738–753 (2022). · DOI
  13. Jeong, M. et al. Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications. Adv. Drug Deliv. Rev. 200, 114990 (2023). · DOI · Paper page
  14. Liu, M. et al. Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy. Sci. Adv. 10, eadk2444 (2024). · DOI
  15. Sasaki, K. et al. mRNA-loaded lipid nanoparticles targeting dendritic cells for cancer immunotherapy. Pharmaceutics 14, 1572 (2022). · DOI
  16. Yu, X. et al. Poly(ethyl ethylene phosphate): overcoming the ‘polyethylene glycol dilemma’ for cancer immunotherapy and mRNA vaccination. ACS Nano 17, 23814–23828 (2023). · DOI
  17. Hald Albertsen, C. et al. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv. Drug Deliv. Rev. 188, 114416 (2022). · DOI · Paper page
  18. Tenchov, R. et al. PEGylated lipid nanoparticle formulations: immunological safety and efficiency perspective. Bioconjug. Chem. 34, 941–960 (2023). · DOI · Paper page
  19. Elzoghby, A. O. et al. Albumin-based nanoparticles as potential controlled release drug delivery systems. J. Control. Release 157, 168–182 (2012). · DOI · Paper page
  20. Abdallah, M. et al. Lymphatic targeting by albumin-hitchhiking: applications and optimisation. J. Control. Release 327, 117–128 (2020). · DOI · Paper page
  21. Famta, P. et al. Albumin-hitchhiking: fostering the pharmacokinetics and anticancer therapeutics. J. Control. Release 353, 166–185 (2022). · DOI · Paper page
  22. Qi, S. et al. The bright future of nanotechnology in lymphatic system imaging and imaging-guided surgery. J. Nanobiotechnol. 20, 24 (2022). · DOI
  23. Zhu, G. et al. Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy. Nat. Commun. 8, 1954 (2017).
  24. Um, W. et al. A comparative study on albumin-binding molecules for targeted tumor delivery through covalent and noncovalent approach. Bioconjug. Chem. 30, 3107–3118 (2019). · DOI
  25. Liu, H. et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507, 519–522 (2014). · DOI · Paper page
  26. Song, Y. et al. Albumin nanoparticle containing a PI3Kγ inhibitor and paclitaxel in combination with α-PD1 induces tumor remission of breast cancer in mice. Sci. Transl. Med. 14, eabl3649 (2022). · DOI
  27. Lin, T. et al. Blood–brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy. ACS Nano 10, 9999–10012 (2016). · DOI · Paper page
  28. Liu, Z. & Chen, X. Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy. Chem. Soc. Rev. 45, 1432–1456 (2016). · DOI · Paper page
  29. Liu, Y. et al. Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion. Nat. Nanotechnol. 17, 206–216 (2022). · DOI
  30. Bern, M. et al. The role of albumin receptors in regulation of albumin homeostasis: implications for drug delivery. J. Control. Release 211, 144–162 (2015). · DOI · Paper page
  31. Ishima, Y. et al. The new delivery strategy of albumin carrier utilizing the interaction with albumin receptors. Chem. Pharm. Bull. 70, 330–333 (2022). · DOI
  32. Wan, Y. et al. Stable organic photosensitizer nanoparticles with absorption peak beyond 800 nanometers and high reactive oxygen species yield for multimodality phototheranostics. ACS Nano 14, 9917–9928 (2020). · DOI · Paper page
  33. Nguyen, L. N. M. et al. The exit of nanoparticles from solid tumours. Nat. Mater. 22, 1261–1272 (2023). · DOI · Paper page
  34. Embgenbroich, M. & Burgdorf, S. Current concepts of antigen cross-presentation. Front. Immunol. 9, 1643 (2018). · DOI · Paper page
  35. Oğuz, F. & Atmaca, H. mRNA as a therapeutics: understanding mRNA vaccines. Adv. Pharm. Bull. 12, 274–282 (2022).
  36. Szymonowicz, K. A. & Chen, J. Biological and clinical aspects of HPV-related cancers. Cancer Biol. Med. 17, 864 (2020). · DOI · Paper page
  37. Mirabello, L. et al. HPV16 E7 genetic conservation is critical to carcinogenesis. Cell 170, 1164–1174 (2017). · DOI · Paper page
  38. Feshchenko, E. et al. Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability. BMC Biotechnol. 12, 77 (2012). · DOI
  39. Cyster, J. G. & Allen, C. D. C. B cell responses: cell interaction dynamics and decisions. Cell 177, 524–540 (2019). · DOI · Paper page
  40. Mittenbühler, M. J. et al. Isolation of extracellular fluids reveals novel secreted bioactive proteins from muscle and fat tissues. Cell Metab. 35, 535–549 (2023). · DOI
  41. Renier, N. et al. iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging. Cell 159, 896–910 (2014). · DOI · Paper page

Cited by

See all 66

Metadata

Authors
Feng, Y., Tai, W., Huang, P., Qi, S., Yu, X., Li, M., Li, M., Zhang, M., Cao, F., Gao, X., Yang, K., Bai, B., Lei, J., Cheng, M., Li, Y., Cheng, G., Chen, X., & Yu, G.
Venue
Nature Materials
Published
2025-08-01
Volume
24
Issue
11
Pages
1826-1839
ISSN
  • 1476-1122
  • 1476-4660
Cited by
66
References
12
Language
en
Licence
Funders
National University of Singapore (NUHSRO/2020/133/Startup/08)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Albumin-recruiting lipid nanoparticle potentiates the safety and efficacy of mRNA vaccines by avoiding liver accumulation. https://app.cochat.ai/papers/10.1038/s41563-025-02284-w
The paper
Feng, Y., Tai, W., Huang, P., Qi, S., Yu, X., Li, M., Li, M., Zhang, M., Cao, F., Gao, X., Yang, K., Bai, B., Lei, J., Cheng, M., Li, Y., Cheng, G., Chen, X., & Yu, G. (2025). Albumin-recruiting lipid nanoparticle potentiates the safety and efficacy of mRNA vaccines by avoiding liver accumulation. Nature Materials. https://doi.org/10.1038/s41563-025-02284-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.